| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff81a650b70e913d3b2524b45e4c7320 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-907
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate |
2020-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a420ba53716fa3057bbf2d354d738f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0bace4c7dd67818aa6fe097b2b68927b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_13e4f38a91b03b08b4b902b38a1e7bb3 |
| publicationDate |
2020-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020264186-A1 |
| titleOfInvention |
Cells engineered for oligonucleotide delivery, and methods for making and using thereof |
| abstract |
The present disclosure is directed to genetically modified carrier/donor cells that are engineered to be resistant to its oligonucleotide payload, and methods of delivering an oligonucleotide into a target cell. The disclosure is also directed to methods of treating cancer using the engineered carrier cells of the disclosure. An aspect of this disclosure is directed to engineering carrier cells to be resistant to the detrimental effects of an oligonucleotide. |
| priorityDate |
2019-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |